Spotlight



In this issue of GOLD, we reflect on the pharmaceutical industry’s key developments over the last few months, guiding you through all the latest COVID-19 vaccine announcements, as well as FDA-approval updates, acquisitions, and significant appointments.



23 November

Pharma’s R&D spending shows a 6.9% increase, reaching an 8-year high


24 November

The EU secures up to 160 million doses of Moderna’s mRNA COVID-19 vaccine


01 December

The FDA approve use of Genentech’s Xolair for adults with nasal polyps


10 December

Sanofi and GSK announce delay of COVID-19 vaccine until end of 2021 due to insufficient immune responses


12 December

AstraZeneca extend rare diseases portfolio with $39 billion acquisition of Alexion


06 January

Redesigned logo for Pfizer sees the introduction of DNA double helix emblem


07 January

Amgen’s Corinne Le Goff announced to join Moderna as Chief Commercial Officer


07 January

Roche’s Actemra and Sanofi and Regeneron’s Kevzara show to significantly improve survival in patients with COVID-19


08 January

Data suggests Pfizer and BioNTech’s vaccine still effective against South Africa and UK variants


12 January

1.25 million doses of Regeneron’s Casirivimab and Imdevimab antibody cocktail sold to US government for $2.63 billion


21 January

FDA gives approval to GSK’s long-acting HIV injectable, Cabenuva


25 January

Moderna’s COVID-19 vaccine is found to still offer sufficient protection against variants first identified in the UK and South Africa